The nation of Zimbabwe has declined a major US healthcare agreement valued at $367m (£272m) spanning five years due to the United States' request for sensitive data.
The decision became public after a official document dated December was leaked, which showed President Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman later clarified that the United States was seeking health data for scientific study and commercial purposes while was unwilling to guarantee the benefits from future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged further talks to find a agreement suitable to both sides so the country's critical HIV programme can proceed.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a high court suspended a related health funding agreement after legal challenges were raised about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government deals to boost openness and accountability.
Based on reports, 16 African countries have to date agreed to these new agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent assurance of access to any medical innovations – such as new medicines or tests – that might result from that provided information," he stated.
"In essence, our country would provide the raw materials for scientific discovery with no assurance that the end products would be accessible to our population if a new disease outbreak emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of one-on-one deals were upending structures already established via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We welcome further discussions with our American counterparts on how future collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Response
Medical experts said it understood the government's concerns, but recommended that talks need to persist since much of the nation's Aids initiatives relied on external financing.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group commented.
The halted deal emphasises the ongoing debate between accepting vital foreign assistance and protecting a country's data in an ever more data-driven world.